KeyBanc Keeps Their Buy Rating on Resmed (RMD)

In a report released today, Brett Fishbin from KeyBanc maintained a Buy rating on Resmed (RMD – Research Report), with a price target of $238.00. The company’s shares closed yesterday at $183.42.

Fishbin covers the Healthcare sector, focusing on stocks such as Integer Holdings, Cooper Co, and ICU Medical. According to TipRanks, Fishbin has an average return of 4.3% and a 71.43% success rate on recommended stocks.

In addition to KeyBanc, Resmed also received a Buy from Bank of America Securities’s Lyanne Harrison in a report issued on April 17. However, on April 10, RBC Capital maintained a Hold rating on Resmed (NYSE: RMD).

Based on Resmed’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.16 billion and a net profit of $208.8 million. In comparison, last year the company earned a revenue of $1.03 billion and had a net profit of $224.91 million

Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RMD in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Resmed (RMD) Company Description:

Founded in 1989, California-based ResMed, Inc. is a medical equipment company. The company is engaged in the development, manufacturing, distribution, and marketing of medical equipment and software solutions. The company operates through two segments: Sleep and Respiratory Care, and SaaS (Software as a Service).